Advertisement
Financing › Details
Santhera–SEVERAL: credit, 201702–202202 senior unsecured convertible bonds CHF60m 5% due 202202
Period | 2017-02-10 � 2022-02-17 | |
Money taker | Santhera Pharmaceuticals Holding AG (SIX: SANN) | |
Group | Santhera (Group) | |
Money source | SEVERAL | |
Product | investment banking | |
Source | Reuters. (2/10/17). "News: BRIEF – Santhera Successfully Places 60 mln Swiss Francs Senior Convertible Bonds". | |
Record changed: 2023-02-13 |
Advertisement
More documents for Santhera (Group)
- [1] Santhera Pharmaceuticals Holding AG. (10/27/23). "Press Release: Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy [Ad hoc announcement pursuant to Art. 53 LR]". Pratteln....
- [2] Santhera Pharmaceuticals Holding AG. (6/20/23). "Press Release: Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties [Ad hoc announcement pursuant to Art. 53 LR]...
- [3] Santhera Pharmaceuticals Holding AG. (1/4/22). "Press Release: Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region". Pratteln....
- [4] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
- [5] Santhera Pharmaceuticals Holding AG. (10/6/20). "Press Release: Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone". Pratteln....
- [6] Santhera Pharmaceuticals Holding AG. (1/24/20). "Press Release: Santhera Appoints New Chief Financial Officer". Pratteln....
- [7] Santhera Pharmaceuticals AG. (11/4/19). "Press Release: Santhera Appoints New Chief Executive Officer". Pratteln....
- [8] Santhera Pharmaceuticals Holding AG. (12/14/18). "Press Release: Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license". Pratteln....
- [9] Santhera Pharmaceuticals Holding AG. (12/12/18). "Press Release: Santhera Announces Financial Results for the First Nine Months of 2018". Pratteln....
- [10] Santhera Pharmaceuticals Holding AG. (11/21/18). "Press Release: Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone". Pratteln & Allschwil....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top